1. Home
  2. NRIX vs ANGI Comparison

NRIX vs ANGI Comparison

Compare NRIX & ANGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • ANGI
  • Stock Information
  • Founded
  • NRIX 2009
  • ANGI 1995
  • Country
  • NRIX United States
  • ANGI United States
  • Employees
  • NRIX N/A
  • ANGI N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • ANGI Advertising
  • Sector
  • NRIX Health Care
  • ANGI Consumer Discretionary
  • Exchange
  • NRIX Nasdaq
  • ANGI Nasdaq
  • Market Cap
  • NRIX 728.6M
  • ANGI 791.5M
  • IPO Year
  • NRIX 2020
  • ANGI 2017
  • Fundamental
  • Price
  • NRIX $10.69
  • ANGI $14.33
  • Analyst Decision
  • NRIX Strong Buy
  • ANGI Hold
  • Analyst Count
  • NRIX 14
  • ANGI 8
  • Target Price
  • NRIX $29.07
  • ANGI $21.17
  • AVG Volume (30 Days)
  • NRIX 1.2M
  • ANGI 910.4K
  • Earning Date
  • NRIX 10-09-2025
  • ANGI 11-10-2025
  • Dividend Yield
  • NRIX N/A
  • ANGI N/A
  • EPS Growth
  • NRIX N/A
  • ANGI N/A
  • EPS
  • NRIX N/A
  • ANGI 1.20
  • Revenue
  • NRIX $88,381,000.00
  • ANGI $1,088,722,000.00
  • Revenue This Year
  • NRIX $74.59
  • ANGI N/A
  • Revenue Next Year
  • NRIX N/A
  • ANGI $4.89
  • P/E Ratio
  • NRIX N/A
  • ANGI $11.77
  • Revenue Growth
  • NRIX 41.86
  • ANGI N/A
  • 52 Week Low
  • NRIX $8.18
  • ANGI $10.88
  • 52 Week High
  • NRIX $29.56
  • ANGI $27.10
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 63.25
  • ANGI 29.26
  • Support Level
  • NRIX $8.20
  • ANGI $13.78
  • Resistance Level
  • NRIX $10.23
  • ANGI $16.47
  • Average True Range (ATR)
  • NRIX 0.50
  • ANGI 0.65
  • MACD
  • NRIX 0.27
  • ANGI -0.27
  • Stochastic Oscillator
  • NRIX 99.80
  • ANGI 13.30

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

Share on Social Networks: